News | October 03, 2014

Accreditation for Cardiovascular Excellence (ACE) Selected by CMS to accredit CREST-2 Registry Clinical Sites

CMS selects ACE to accredit CREST-2 Registry clinical sites

October 3, 2014 — The Centers for Medicare & Medicaid Services (CMS) has determined that clinical sites that wish to participate in the newly announced CREST-2 carotid artery stenting (CAS) registry must receive accreditation. Accreditation for Cardiovascular Excellence (ACE) is a designated organization to provide these reviews. The objective of the CREST-2 Registry is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial. Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with CAS performed by experienced and skilled interventionists.

Interventionists' eligibility will be determined by the multi-specialty CREST-2 Interventional Management Committee. Patient eligibility will include patients with conventional or high risk, symptomatic and asymptomatic carotid artery disease. Individual interventionist safety and quality results from the CREST-2 Registry will help guide selection of interventionists for participation in the CREST-2 randomized clinical trial. Enrollment into the CREST-2 Registry will begin in 2014.

"ACE accreditation process demonstrates a program's commitment to achieving the highest standards of care," says Bonnie H. Weiner, M.D., MSEC, MBA, MSCAI, FACC, and ACE's chief medical officer. "ACE is proud to be an organization recognized by CMS to improve quality outcomes by providing expert guidance to facilities seeking accreditation for CAS."

Citing national accreditation and external review as an accepted strategy for program quality assurance, ACE is viewed as the standard-bearer for achieving quality metrics in CAS. ACE delivers unique programs that help facilities comply with documentation to meet Appropriate Use Criteria (AUC) while elevating the performance of interventional catheterization labs by integrating standardized care. The result is a cost-effective program that mitigates risk.

For more information: www.cvexcel.org


Related Content

News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
Subscribe Now